Thus, we provide further evidence for the impairment of induced Treg (iTreg)-mediated immunoregulation by TLR7 ligands which is in accordance with the previous results 19, 34. Furthermore, we identify additional mechanisms for the reduction of Treg-mediated suppression by TLR7 activation, which are not mediated by resistance of responder T cells to Tregs. Our study shows ABT-888 cost that TLR7-mediated activation of DCs reduces immunoregulation by Tregs at the levels of Treg generation as well as suppressive function thus contributing to the breakdown of peripheral tolerance and development of autoimmunity, for example, in SLE, where activation of TLR7 by endogenous ligands was shown to play

a role in the pathogenesis. Therapeutic approaches aiming to reverse Foxp3 downregulation by interfering with TLR7 activation or by blocking downstream

effector cytokines such as IL-6 are therefore promising strategies for the treatment of SLE. C57BL/6 and BALB/c mice were purchased from Harlan Winkelmann (Borchen, Germany). TLR7−/−35, DEREG 23.2 (both on the C57BL/6 background) 36, DO11.10/Rag2−/−, OTII/Rag2−/−/DEREG, and CD45.1 congenic mice were bred in our animal facility Z-IETD-FMK research buy under specific pathogen-free conditions. Experiments were performed in accordance with the German animal care and ethics legislation and had been approved by the local government authorities. CD11c+ DCs were isolated from splenocytes after digestion with DNAse I and collagenase D (Roche Applied Science, Mannheim, Germany) using anti-CD11c-coupled magnetic beads (Miltenyi Biotec, Bergisch-Gladbach, Germany, purity 90–98%). CD4+CD25− T cells Tenoxicam were isolated using the CD4+ T-cell isolation kit (Miltenyi Biotec) supplemented with biotinylated anti-CD25 antibody (eBioscience, San Diego, CA, USA, purity 90–95%). Naïve T cells were stimulated with 5 μg/mL anti-CD3 antibody (eBioscience) coated to the surface of a 96-well round-bottom plate together with CD11c+ splenic DCs at a ratio of 2:1 (80 000 T cells and

40 000 DCs) or 5 μg/mL soluble anti-CD28 antibody (eBioscience) in 200 μL/well complete medium (RPMI1640, 10% FBS, 1% glutamax, 1% penicillin/streptomycin, 1% non-essential amino acids, 1% sodium pyruvate, 50 μM β-mercaptoethanol) with TGF-β (3–5 ng/mL, Peprotech, Hamburg, Germany) and IL-2 (200 U/mL, PromoKine, PromoCell GmbH, Heidelberg, Germany). The following TLR ligands were used: TLR7 ligand S-27609 (3 μM, imiquimod analogue, 3 M Pharmaceuticals, St. Paul, MN, USA), TLR9 ligand CpG 1668 (0.5 μM, MWG Operon, Ebersberg, Germany) and TLR4 ligand LPS (100 ng/mL, Sigma-Aldrich, St. Louis, MO, USA). Where indicated, 40 μg/mL U1snRNP (gift of Bertold Kastner, Berlin, Germany) complexed with 12.5 μg/mL cationic lipid DOTAP (Roth, Karlsruhe, Germany) was used to stimulate the cells 5. IL-6 was neutralized by anti-IL-6 (5 μg/mL) together with anti-IL-6R antibody (2 μg/mL).